Kerendia comes as a tablet that you swallow. The active ingredient in Kerendia is finerenone. (An active ingredient is what makes a drug work.) Kerendia is a brand-name drug that’s not available in a ...

Kerendia (finerenone) is a prescription drug that’s used to reduce certain risks in adults with type 2 diabetes. Kerendia can cause mild to serious side effects. Examples include high potassium levels ...

Bayer building in Reading, UK. Thousands of people in England and Wales with a type of chronic heart failure (CHF) could soon be eligible for treatment with Bayer's Kerendia, a new type of drug that ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has reached the market that could further alter the HF landscape. The FDA has ...

Kerendia (finerenone) is a brand-name oral tablet that’s prescribed to reduce certain risks in adults with type 2 diabetes. The cost of the drug with and without insurance can depend on several ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's sales prospects. The US regulator has ...

Before you start treatment with Kerendia, your doctor will recommend the best dosage of medication for you. They will also discuss the frequency of administration with you. The following information ...

Approved two summers ago for chronic kidney disease (CKD) associated with type 2 diabetes, Bayer’s Kerendia (finerenone) isn’t off to the flying start expected of a potential blockbuster. In the ...

Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA ® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Bayer (XTRA:BAYN) reported ...

KERENDIA ® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline to Month 32 – ...